Evidence map›Paper›PMID 39014292›Full record

ArticleLa Radiologia medica2024

Association between mpMRI detected tumor apparent diffusion coefficient and 5-year biochemical recurrence risk after radical prostatectomy.

Sarah Alessi, Roberta Maggioni, Stefano Luzzago, Paul E Summers, Giuseppe Renne, Fabio Zugni, Maddalena Belmonte, Sara Raimondi, Silvano Vignati, Francesco A Mistretta and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in La Radiologia medica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Chromatin regulatorsChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sarah AlessiDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy. sarah.alessi@ieo.it.ORCID http://orcid.org/0000-0001-9517-4203
Roberta MaggioniDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Stefano LuzzagoDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Paul E SummersDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.ORCID http://orcid.org/0000-0002-5085-1095
Giuseppe RenneDivision of Uropathology and Intraoperative Diagnostic Division, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Fabio ZugniDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Maddalena BelmonteDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Sara RaimondiMolecular and Pharmaco-Epidemiology Unit Department of Experimental Oncology IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Silvano VignatiMolecular and Pharmaco-Epidemiology Unit Department of Experimental Oncology IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Francesco A MistrettaDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Letizia Di MeglioPostgraduation School in Radiodiagnostics, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Elisa D'AscoliPostgraduation School in Radiodiagnostics, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Alice ScarabelliPostgraduation School in Radiodiagnostics, University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.
Giulia MarvasoDivision of Radiation Oncology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Ottavio De CobelliDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Gennaro MusiDepartment of Urology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.
Barbara Alicja Jereczek-FossaDepartment of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, 20122, Milan, Italy.
Giuseppe PetraliaDivision of Radiology, IEO European Institute of Oncology, IRCCS, Via Ripamonti 435, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo assess the ability of tumor apparent diffusion coefficient (ADC) values obtained from multiparametric magnetic resonance imaging (mpMRI) to predict the risk of 5-year biochemical recurrence (BCR) after radical prostatectomy (RP). MATERIALS AND

methodsThis retrospective analysis included 1207 peripheral and 232 non-peripheral zone prostate cancer (PCa) patients who underwent mpMRI before RP (2012-2015), with the outcome of interest being 5-year BCR. ADC was evaluated as a continuous variable and as categories: low (< 850 µm

resultsAmong the 1439 males with median age 63 (± 7) years, the median follow-up was 59 months, and 306 (25%) patients experienced BCR. Peripheral zone PCa patients with BCR had lower tumor ADC values than those without BCR (874 versus 1025 µm

conclusionTumor ADC values and categories were found to be predictive of the 5-year BCR risk after RP in patients with peripheral zone PCa and may serve as a prognostic biomarker.

Indexed as

Multiparametric Magnetic Resonance ImagingNeoplasm Recurrence, LocalProstatectomyProstatic NeoplasmsAgedDiffusion Magnetic Resonance ImagingHumansMaleMiddle AgedProstate-Specific AntigenRetrospective StudiesRisk AssessmentProstate-Specific AntigenApparent diffusion coefficientBiochemical recurrenceMultiparametric prostate MRIProstate cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.